Recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) Homo sapiens (Human) Recombinant protein

EPAS1; HLF; MOP2; PASD2; BHLHE73; Endothelial PAS Domain 1; HIF-1 Alpha-Like Factor; Basic-helix-loop-helix-PAS protein MOP2; Class E basic helix-loop-helix protein 73

  • UOM
    1. 10µg
    2. 50µg
    3. 200µg
    4. 1mg
    5. 5mg
  • FOB US$ 140.00 US$ 350.00 US$ 700.00 US$ 2,100.00 US$ 5,250.00
  • Quantity
    In stock
Add to Cart Distributors Free trial
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Molecular Mass n/a, Accurate n/a(Analysis of differences refer to the manual)
  • Residues & TagsN-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Pointn/a
Share your citation Upload your experimental result Review Leave a message

Share a new citation as an author

Upload your experimental result


Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

E-mail address*
Verification code* CheckCode
  • Recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) Packages (Simulation)
  • Recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered



Reconstitute in PBS or others.


Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.


The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.


  • Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingPubMed: 26409567
  • Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trialissn:2542-3975

Recommend products